These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33323861)

  • 1. Digital Quantification of Ki-67 and PHH3 in the Classification of Uterine Smooth Muscle Tumors.
    Cao CD; Rico-Castillo J; De Cotiis D; Richard SD; Rosenblum NG; Chan JSY
    Int J Gynecol Pathol; 2021 Nov; 40(6):549-555. PubMed ID: 33323861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.
    Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX
    Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
    Petrović D; Babić D; Forko JI; Martinac I
    Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.
    Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP
    Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm).
    Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM
    J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.
    Veras E; Malpica A; Deavers MT; Silva EG
    Int J Gynecol Pathol; 2009 Jul; 28(4):316-21. PubMed ID: 19483635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
    Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
    Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei.
    Lintel NJ; Luebker SA; Lele SM; Koepsell SA
    Hum Pathol; 2018 Mar; 73():122-127. PubMed ID: 29307622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leiomyoma with nuclear atypia: Rare diseases that present a common diagnostic problem.
    Wei JJ
    Semin Diagn Pathol; 2022 May; 39(3):187-200. PubMed ID: 35144823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
    Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
    Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.
    Rubisz P; Ciebiera M; Hirnle L; Zgliczyńska M; Łoziński T; Dzięgiel P; Kobierzycki C
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
    Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
    J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fascin expression in uterine smooth muscle tumors.
    Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
    Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
    Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
    Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.